Sanofi continues to push the boundaries of drug discovery by acquiring another AI startup.
Sanofi has entered into a partnership with Aqemia, a Paris-based startup specializing in quantum physics algorithms and generative AI for drug discovery. Sanofi plans to use Aqemia’s, spun out of École normale supérieure in 2019, tech to discover small molecules in various therapeutic areas.
The $140 million collaboration taps into the booming AI drug discovery market expected to reach $15.44 billion by 2032, ushering a new era of faster, more effective drug development.
“This whole new step is about scaling our respective expertise to multiple projects and supporting Sanofi in discovering novel chemical matter at scale with our unique technology – including on difficult projects with limited chemical data upfront and hard issues like selectivity,” said Maximilien Levesque, Aqemia CEO and Co-founder.
Sanofi continues to push the boundaries of drug discovery with more AI acquisitions.